“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...
US pharma major GSK yesterday announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant ...
Hosted on MSN2d
GSK’s Arexvy Vaccine Shows Promise for Broader UseGlaxoSmithKline (GB:GSK) has released an update. GSK has announced promising new data for its RSV vaccine, Arexvy, which ...
GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...
While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to ...
Medpage Today on MSN3d
FDA Expands Approval of RSV Vaccine Abrysvo to Include All At-Risk AdultsThe FDA expanded the approval of the bivalent RSV prefusion F (RSVpreF) vaccine (Abrysvo) to include the prevention of lower ...
Arexvy is currently approved for active immunization for the prevention of LRTD caused by RSV in individuals 60 years of age and older, and those 50 to 59 years of age who are at increased risk for ...
Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people ...
A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival ...
The CDC’s vaccine advisors on Thursday maintained that respiratory syncytial virus immunization is only recommended for ...
New data for Arexvy, GSK’s RSV vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease: London, UK Friday, October 25, 2024, 13:00 Hr ...
Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback